🚨 New article in Haematologica: Myeloma patients with extramedullary disease face more severe toxicities and worse outcomes after BCMA CAR-T therapy, including more ICANS, prolonged cytopenias, more inflammation, and worse non-relapse mortality. Read more: haematologica.org/article/view...

Sometimes in Seattle you find your spirit animal.

🔬 Science Spotlight: A real-world, 3-year analysis compares axi-cel & liso-cel for relapsed LBCL. Both CAR T-cell therapies were equally effective, but liso-cel had a better safety profile, with less CRS, neurotoxicity, and need for supportive care. 🔗 www.fredhutch.org/en/news/spot...